422 related articles for article (PubMed ID: 34480880)
1. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
Ramacciotti E; Agati LB; Calderaro D; Volpiani GG; de Oliveira CCC; Aguiar VCR; Rodrigues E; Sobreira ML; Joviliano EE; Dusilek C; Itinose K; Dedivitis RA; Cortina AS; Sanches SMV; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; Cavalcante BBM; Moreira RCR; Chiann C; Tafur A; Spyropoulos AC; Lopes RD
Am Heart J; 2021 Dec; 242():115-122. PubMed ID: 34480880
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
3. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
[TBL] [Abstract][Full Text] [Related]
6. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Capell WH; Barnathan ES; Piazza G; Spyropoulos AC; Hsia J; Bull S; Lipardi C; Sugarmann C; Suh E; Rao JP; Hiatt WR; Bonaca MP
Am Heart J; 2021 May; 235():12-23. PubMed ID: 33577800
[TBL] [Abstract][Full Text] [Related]
10. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Perrotta C; Chahla J; Badariotti G; Ramos J
Cochrane Database Syst Rev; 2020 May; 5(5):CD005259. PubMed ID: 32374919
[TBL] [Abstract][Full Text] [Related]
11. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K; Spyropoulos AC
Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
[TBL] [Abstract][Full Text] [Related]
13. Eligibility for Posthospitalization Venous Thromboembolism Prophylaxis in Hospitalized Patients With COVID-19: A Retrospective Cohort Study.
Vaughn VM; Ratz D; McLaughlin ES; Horowitz JK; Flanders SA; Middleton EA; Grant PJ; Kaatz S; Barnes GD
J Am Heart Assoc; 2022 Oct; 11(19):e025914. PubMed ID: 36073649
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
15. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
Piazza G; Spyropoulos AC; Hsia J; Goldin M; Towner WJ; Go AS; Bull TM; Weng S; Lipardi C; Barnathan ES; Bonaca MP;
Circulation; 2023 Jun; 147(25):1891-1901. PubMed ID: 37154020
[TBL] [Abstract][Full Text] [Related]
18. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?
Sharma A; Chatterjee S; Lichstein E; Mukherjee D
J Thromb Haemost; 2012 Oct; 10(10):2053-60. PubMed ID: 22863355
[TBL] [Abstract][Full Text] [Related]
19. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
20. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]